Skip to main content

Table 3 Geometric means (95 % CI) of volumetric mammographic density measures by current statin use

From: Effects of statin use on volumetric mammographic density: results from the KARMA study

  

Geometric mean (95 % CI)a

  

Model 1

Model 2

Model 3

Model 4

 

Statin use

    

Percent dense volume (%)

No

8.01 (7.97–8.05)

7.93 (7.90–7.96)

7.93 (7.90–7.96)

7.94 (7.91–7.97)

 

Yes

6.89 (6.77–7.01)

7.73 (7.63–7.84)

7.74 (7.63–7.85)

7.66 (7.54–7.77)

 

P value

<0.001

0.001

0.001

<0.001

Absolute dense volume (cm3)

No

56.8 (56.6–57.1)

57.1 (56.8–57.3)

57.1 (56.8–57.3)

57.0 (56.8–57.3)

 

Yes

60.7 (59.7–58.5)

57.6 (56.7–58.5)

57.5 (56.7–58.4)

58.0 (57.0–59.0)

 

P value

<0.001

0.31

0.32

0.06

Absolute non-dense volume (cm3)

No

643 (639–647)

653 (650–656)

653 (650–656)

652 (649–655)

 

Yes

808 (791–826)

676 (666–686)

675 (665–685)

689 (678–700)

 

P value

<0.001

<0.001

<0.001

<0.001

 

Statin type

    

Percent dense volume (%)

None

8.01 (7.98–8.05)

7.93 (7.90–7.97)

7.93 (7.90–7.97)

7.94 (7.91–7.97)

Lipophilic

6.92 (6.80–7.04)

7.73 (7.65–7.87)

7.77 (7.66–7.88)

7.69 (7.57–7.81)

Hydrophilic

6.46 (6.05–6.89)

7.32 (6.94–7.71)

7.34 (6.97–7.73)

7.26 (6.90–7.65)

 

P value

<0.001

<0.001

<0.001

<0.001

Absolute dense volume (cm3)

None

56.8 (56.6–57.1)

57.1 (56.8–57.3)

57.1 (56.8–57.3)

57.0 (56.8–57.3)

Lipophilic

60.8 (59.8–61.8)

57.7 (56.8–58.6)

57.7 (56.8–58.6)

58.1 (57.2–59.1)

Hydrophilic

58.2 (54.7–61.8)

55.0 (51.9–58.3)

54.8 (51.8–58.1)

55.3 (52.2–58.6)

 

P value

<0.001

0.20

0.66

0.21

Absolute non-dense volume (cm3)

None

643 (639–647)

653 (650–656)

653 (650–656)

652 (649–655)

Lipophilic

807 (789–825)

675 (664–685)

674 (664–685)

688 (676–699)

Hydrophilic

830 (765–900)

683 (646–723)

679 (642–718)

693 (655–733)

 

P value

<0.001

<0.001

0.03

0.003

 

Statin duration

    

Percent dense volume (%)

None

8.01 (7.97–8.05)

7.93 (7.90–7.96)

7.93 (7.90–7.96)

7.94 (7.91–7.97)

 

<2 years

7.00 (6.71–7.31)

7.54 (7.29–7.81)

7.64 (7.38–7.90)

7.57 (7.32–7.84)

 

2–5 years

6.76 (6.58–6.95)

7.59 (7.43–7.76)

7.63 (7.47–7.80)

7.56 (7.40–7.73)

 

>5 years

6.96 (6.79–7.14)

7.92 (7.77–8.08)

7.86 (7.71–8.02)

7.77 (7.61–7.96)

 

P trend

<0.001

0.03

0.01

<0.001

Absolute dense volume (cm3)

None

56.8 (56.6–57.1)

57.1 (56.8–57.3)

57.1 (56.8–57.3)

57.0 (56.8–57.3)

 

<2 years

58.5 (56.2–60.9)

56.6 (54.5–58.8)

57.0 (54.9–59.2)

57.3 (55.2–59.5)

 

2–5 years

60.6 (59.1–62.2)

57.5 (56.2–58.9)

57.8 (56.4–59.2)

58.2 (56.8–59.7)

 

>5 years

61.4 (60.0–62.9)

57.9 (56.6–59.2)

57.5 (56.2–58.8)

58.0 (56.7–59.4)

 

P trend

<0.001

0.20

0.32

0.06

Absolute non-dense volume (cm3)

None

643 (639–647)

653 (650–656)

653 (650–656)

652 (649–655)

<2 years

767 (727–809)

683 (659–709)

680 (655–705)

689 (664–715)

 

2–5 years

825 (798–854)

690 (674–706)

689 (673–705)

702 (685–719)

 

>5 years

809 (784–834)

661 (647–676)

663 (649–677)

678 (662–693)

 

P trend

<0.001

0.001

<0.001

<0.001

  1. aAll volumetric mammographic density measures were log transformed for analysis and the values shown are on a back-transformed scale
  2. P value refers to F-test for between-statin group differences in geometric means, while P trend refers to linear trend analyses entering statin duration (<2 years, 2–5years, > 5 years) as continuous term in the analysis
  3. Model 1: adjusted for age (years)
  4. Model 2: Model 1 + body mass index (kg/m2)
  5. Model 3: Model 2 + menopausal status (pre, peri/unknown, post), HRT use (never, former, current), parity/age at first birth (nulliparous, 1 child age at first birth < 25 years, 1 child age at first birth ≥ 25 years, 2 children age at first birth < 25 years , 2 children age at first birth ≥ 25 years, ≥ 3 children age at first birth < 25 years, ≥ 3 children age at first birth ≥ 25 years), age at menarche (years), education level (compulsory, gymnasium, university), smoking (never, former, current), alcohol consumption (nondrinker, 0,1–1,9 g/day, 2.0–4.9 g/day, 5.0–9.9 g/day, ≥10 g/day) and benign breast disease (yes vs. no) +
  6. Model 4: Model 3 plus low-dose aspirin (yes vs. no) and metformin use (yes vs. no)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us